Kelsey Stephen Michael 的 Form 4 申報
Revolution Medicines, Inc.（RVMD），2025/9/15 申報
- 申報編號
- 0001610717-25-000339
- 申報時間
- 2025/9/15
- 交易日
- 2025/9/11-9/15
- 申報延遲
- 4 天
- 10b5-1 計畫
- 有勾選
這份申報列了 6 筆非衍生性交易、2 筆衍生性交易。公開市場賣出合計 $555.8 萬。交易後 4 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Kelsey Stephen MichaelCIK 0001462808 | 高階主管（見申報備註） |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2025/9/11 | Common Stock | M行使選擇權取得 | +100,000 | $4.73 | +$473,000 | 389,414 | 直接 | |
| 2025/9/11 | Common Stock | S賣出處分 | −44,059 | $43.58F3 | −$1,920,091.22 | 345,355 | 直接 | |
| 2025/9/11 | Common Stock | S賣出處分 | −55,941 | $44.48F4 | −$2,488,255.68 | 289,414 | 直接 | |
| 2025/9/15 | Common Stock | M行使選擇權取得 | +25,000 | $4.73 | +$118,250 | 314,414 | 直接 | |
| 2025/9/15 | Common Stock | S賣出處分 | −23,682 | $45.92F5 | −$1,087,477.44 | 290,732 | 直接 | |
| 2025/9/15 | Common Stock | S賣出處分 | −1,318 | $46.93F6 | −$61,853.74 | 289,414 | 直接 |
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2025/9/11 | Common Stock | M行使選擇權處分 | −100,000 | $0.00 | $0 | 55,055 | 直接 | |
| 2025/9/15 | Common Stock | M行使選擇權處分 | −25,000 | $0.00 | $0 | 30,055 | 直接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F3
The transaction was executed in multiple trades in prices ranging from $43.12 to $44.09, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F4
The transaction was executed in multiple trades in prices ranging from $44.12 to $44.99, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F5
The transaction was executed in multiple trades in prices ranging from $45.4650 to $46.46, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F6
The transaction was executed in multiple trades in prices ranging from $46.5450 to $47.21, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
備註
President, Research and Development